AIM AND SCOPE

The Journal of Oncogenomics and Oncotarget aims to provide an international, peer-reviewed platform for the publication of high-quality research, clinical studies, and scholarly contributions in the fields of cancer genomics, molecular oncology, and targeted cancer therapies. The journal is dedicated to advancing scientific understanding of the genetic and molecular mechanisms underlying cancer development, progression, metastasis, and therapeutic resistance. It seeks to promote innovative approaches in cancer diagnosis, prevention, prognosis, and treatment through the integration of genomics, precision oncology, and translational cancer research.

The journal aims to bridge the gap between basic cancer research and clinical application by encouraging interdisciplinary and translational studies that contribute to improved patient outcomes, personalized cancer care, and the development of novel therapeutic strategies. Emphasis is placed on scientific rigor, ethical research practices, and the dissemination of findings with significant clinical and societal impact.

The journal also seeks to foster collaboration among oncologists, geneticists, molecular biologists, clinicians, bioinformaticians, pharmaceutical scientists, and healthcare professionals worldwide, enabling the exchange of knowledge and advancements in oncogenomics and targeted oncology.

Scope of the Journal

The journal covers a broad range of topics related to cancer genetics, oncogenomics, molecular oncology, and targeted therapeutics. Areas of interest include, but are not limited to, the following:

Cancer genomics, oncogenomics, molecular oncology, cancer biology, tumor biology, tumor microenvironment, cancer genetics, somatic mutations, germline mutations, oncogenes, tumor suppressor genes, epigenetics in cancer, cancer epigenomics, chromosomal abnormalities in cancer, genomic instability, DNA repair mechanisms, mutational signatures, cancer heterogeneity, clonal evolution, metastasis biology, angiogenesis, apoptosis, cell signaling pathways, signal transduction in cancer, cancer metabolism, cancer stem cells, immuno-oncology, tumor immunology, immune checkpoint pathways, cancer biomarkers, prognostic biomarkers, predictive biomarkers, molecular diagnostics, liquid biopsy, circulating tumor DNA, circulating tumor cells, next-generation sequencing, whole genome sequencing, whole exome sequencing, transcriptomics, proteomics, metabolomics, single-cell sequencing, spatial genomics, multi-omics integration, bioinformatics in oncology, computational oncology, artificial intelligence in cancer research, machine learning in oncology, systems oncology, cancer databases, big data analytics in oncology, precision oncology, personalized cancer medicine, targeted therapy, molecular targeted agents, small molecule inhibitors, kinase inhibitors, monoclonal antibodies, antibody-drug conjugates, cancer vaccines, immunotherapy, adoptive cell therapy, CAR-T cell therapy, gene therapy for cancer, RNA therapeutics, CRISPR and genome editing in oncology, nanomedicine, drug delivery systems, chemotherapeutics, radiogenomics, radiosensitivity, chemotherapy resistance, multidrug resistance, pharmacogenomics in oncology, translational oncology, clinical oncology, clinical cancer genomics, clinical trials, early phase oncology trials, therapeutic response assessment, cancer prevention, cancer epidemiology, hereditary cancer syndromes, familial cancers, pediatric oncology, hematologic malignancies, solid tumors, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer, cervical cancer, liver cancer, pancreatic cancer, gastric cancer, skin cancer, melanoma, leukemia, lymphoma, myeloma, neuro-oncology, endocrine tumors, rare cancers, comparative oncology, viral oncology, infection-associated cancers, environmental carcinogenesis, occupational carcinogens, lifestyle and cancer risk, public health oncology, survivorship research, palliative oncology, cancer rehabilitation, supportive oncology care, ethical issues in oncology research, cancer health disparities, oncology policy and regulation, patient-centered cancer care, and emerging technologies in cancer research and therapeutics.

Types of Manuscripts

The journal accepts a variety of manuscript types including original research articles, review articles, systematic reviews, meta-analyses, case reports, case series, short communications, technical notes, clinical studies, perspectives, editorials, and letters to the editor.

The topics listed above represent the primary areas of interest of the journal; however, the scope is not limited to these areas alone. The journal welcomes submissions from emerging, interdisciplinary, and innovative fields that contribute to the understanding, diagnosis, prevention, and treatment of cancer and related disorders.

Global Perspective and Inclusivity

The journal adopts a global perspective by encouraging submissions from researchers, clinicians, and healthcare professionals across diverse geographic regions. Cancer remains one of the leading global health challenges, with significant variations in incidence, genetic susceptibility, access to treatment, and clinical outcomes among populations worldwide.

By promoting international collaboration and knowledge exchange, the journal aims to address global oncology challenges and reduce disparities in cancer diagnosis, treatment, and care. Studies focusing on population-specific genomic profiles, regional cancer trends, public health interventions, and global cancer prevention strategies are particularly encouraged.

Ethical, Legal, and Social Considerations

Research in oncology and genomics raises important ethical, legal, and social considerations. The journal recognizes the importance of responsible conduct in cancer research and clinical practice and encourages scholarly work addressing ethical challenges in oncogenomics and precision medicine.

Topics such as informed consent, genetic privacy, data protection, equitable access to cancer therapies, ethical use of genomic data, clinical trial ethics, and patient rights are integral to the journal’s ethical framework. Authors are expected to adhere to internationally accepted ethical guidelines and ensure transparency and integrity in research conduct and reporting.

Education and Knowledge Dissemination

The journal is committed to advancing education and knowledge dissemination in oncogenomics and oncology. It aims to serve as a valuable resource for students, educators, researchers, clinicians, and healthcare professionals by publishing informative, evidence-based, and impactful scientific content.

Educational reviews, clinical updates, and articles that simplify complex oncogenomic concepts and provide practical insights into cancer diagnosis and therapy are strongly encouraged. Through continuous learning and scientific communication, the journal contributes to the development of a well-informed oncology research and clinical community.

Quality, Integrity, and Scientific Rigor

Maintaining high standards of quality, transparency, and scientific integrity is a central principle of the journal. All submissions are expected to demonstrate methodological soundness, scientific rigor, originality, and clarity of presentation.

The peer review process is designed to ensure objective and unbiased evaluation of manuscripts while upholding the highest ethical and academic standards. Authors are encouraged to present findings transparently and accurately, thereby contributing to the reliability and credibility of scientific literature in oncology and genomics.

Encouragement of Collaborative Research

The journal actively promotes collaborative and multidisciplinary research efforts that integrate expertise from oncology, genomics, molecular biology, bioinformatics, pharmacology, immunology, pathology, and clinical medicine.

Collaborative studies often provide deeper insights into complex cancer mechanisms and therapeutic strategies. By providing a platform for interdisciplinary collaboration, the journal aims to accelerate scientific discovery and innovation in cancer research and precision oncology.

Adaptability to Advancing Science

The fields of oncogenomics and cancer therapeutics are rapidly evolving due to continuous technological and scientific advancements. The journal remains adaptable to these developments by expanding its scope to include emerging areas of research, novel therapeutic platforms, and advanced genomic technologies.

Authors are encouraged to explore innovative concepts and contribute to the evolving landscape of cancer genomics and targeted therapy. The journal is committed to remaining current with scientific progress and ensuring that its published content reflects the latest advancements in oncology research and clinical practice.